Migraines and cluster headaches can have devastating consequences on people’s lives, and there is a need to educate the public about the impact these disorders can have, said Abraham Nagy, MD, chair of neurology at University of Las Vegas and director of Nevada Headache Institute.
Migraines and cluster headaches can have devastating consequences on people’s lives, and there is a need to educate the public about the impact these disorders can have, said Abraham Nagy, MD, chair of neurology at University of Las Vegas and director of Nevada Headache Institute.
Transcript
There are many types of headache—how much education is needed to help patients understand what type of headache they have and what the best treatment might be?
So, there are many, many kinds of headache disorders out there and I think one of the biggest illnesses that we have as clinicians is educating our own clinicians about headache types and that’s one of the big important aspects of the American Academy of Neurologist. We, as neurologists, become ambassadors for headache disorders to other care providers, and it would be wonderful if we can then have our other care providers help provide a baseline education.
It’s a very big limitation, but I think that migraine disorders and cluster headache disorders are becoming more understood by the public as neurologic disabilities that can have devastating consequences in people’s lives. For a very long time, headache disorders were thought of as nonconsequential events that could just be treated with a minimal line of care or something over the counter.
But now we’re realizing quite a lot more that this is, there’s a significant disability associated with these events, and we’re trying to make strides in educating the population about this.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More